🎯
Oncology
Cancer therapeutics including targeted therapies, immunotherapies, cell therapies, and precision oncology platforms.
Companies
0
Pipeline Drugs
2057
Key People
3562
Oncology Pipeline (2057 drugs)
Commercial: 320Approved: 305Phase 1: 201Preclinical: 149Phase 3: 143Phase 2: 133Phase 1/2: 128Pre-clinical: 107Approved/Commercial: 52Discovery: 39Phase 2/3: 30Research: 21Not Specified: 20Phase 1b: 17Phase 2b: 13Clinical: 12Not specified: 12Development: 11Phase 1b/2: 11Pending Approval: 11Discovery/Preclinical: 10Early Phase: 9N/A: 9Research-Use Only: 9Not Disclosed: 8Pre-clinical (Tool): 8Various: 7Phase 1/2a: 7Preclinical/Phase 1: 5Observational Study: 5Filed/Approved: 5Pre-IND: 5Clinical Validation: 5Pre-clinical Tool: 5Research-Use-Only: 5Phase 1b/2a: 4Lead Optimization: 4Pre-Clinical: 4Undisclosed: 4Sold/Transferred: 4All Phases: 4Various Phases: 3Phase 2a: 3Preclinical/Discovery: 3Commercial (RUO): 3Marketed: 3In development: 3Research Use Only: 3Research/Discovery: 3Service: 3Clinical Research: 3Pre-commercial: 3Poised for Clinical: 3Platform/Tool Development: 3Not Applicable: 3Regulatory: 2Multiple Phases: 2Development/Commercial: 2ANDA Filed/Development: 2Phase III: 2Phase I: 2R&D: 2Phase (Early Clinical): 2Interventional Study: 2ANDA Filed: 2Phase 1a/1b: 2Phase 1a: 2Filed/Development: 2Clinical Development: 2Early Access: 2BLA Submitted: 2Phase 3-ready: 2Preclinical to Phase 1/2: 2Research & Development: 2Indication-Enabling: 2Approved / Commercial: 2Platform: 2Discovery/Pre-clinical: 2Acquisition: 1Phase 1-3: 1Pivotal Phase 2: 1Launch: 1Phase 3/Commercial: 1Filed: 1Commercial/Filed: 1Development to Commercial: 1NDA Submitted: 1Approved/Registration: 1Commercial Launch: 1Phase 1 to Commercial: 1Pre-clinical to Filing: 1Pre-NDA/Phase III: 1Phase I/II: 1Pipeline: 1IND Cleared: 1Commercial/Approved: 1Approved & Development: 1Research/Preclinical: 1Development/Filed: 1Research/Commercial: 1Launched: 1Development & Commercial: 1Emergency Use Authorization (Past): 1Phase 3 / Commercial: 1Non-GMP / Research: 1Discovery to Preclinical: 1NDA Submission: 1Phase 1 / Phase 2: 1Emergency Use Authorization: 1Pivotal: 1Phase 2b-ready: 1In Development: 1Clinical Studies: 1BLA Filed: 1Oncology Program: 1Pre-clinical/Discovery: 1Phase 2b/3: 1Research Collaboration: 1Phase 1/1b: 1Commercial/IVD Development: 1Commercial (IVD): 1Phase 2 (IND Active): 1Phase 2 Ready: 1Pre-clinical / Clinical: 1Exploratory: 1Clinical Trials: 1Pre-clinical / Early Clinical: 1Commercial/Clinical: 1Pre-clinical/Phase 1: 1Phase 1 (inferred): 1Pre-clinical/Research: 1NDA/BLA Filed: 1Pre-clinical to Phase 3: 1Preclinical/Clinical: 1Research/Development: 1Phase 1 (planned): 1Early Research: 1Clinical candidate: 1Development candidate: 1Pivotal Trial: 1Preclinical/Research: 1Pre-registration: 1Pre-ANDA / Filed: 1Approved (China NMPA Review): 1Prescription Product: 1Pivotal Study: 1Pre-clinical / Limited Clinical: 1Discovery/Platform: 1Proof of Principle: 1Preclinical / Phase 1: 1Phase 2/3; Phase 2: 1Planned Phase 3: 1Investigational (Likely Phase 1/2): 1Assay Development: 1Phase 1 / Preclinical: 1Pre-NDA: 1Diagnostic Development: 1Pre-clinical/Development: 1Clinical Investigation: 1IND enabling: 1Advanced Development: 1Commercial Tool: 1Service Offering: 1Platform/Service: 1Service/Diagnostic: 1Platform/Pre-clinical: 1Research Tool: 1Commercial/Development: 1Research/Pre-clinical: 1Approved (NPIP): 1Pilot/Phase 2: 1Compassionate Use: 1Component: 1R&D/Collaboration: 1Pre-clinical / Phase 1: 1Early-Stage (FIH/EFS): 1Early Clinical Development: 1First-in-Human (FIH): 1Under Review: 1R&D / Early Clinical: 1Research & Regulated Studies: 1Early Discovery: 1Preclinical Research: 1Preclinical/Translational: 1Preclinical/Phase 1 planning: 1Phase 2 (planned): 1
Key People in Oncology
AM
Anders Månsson
Chief Executive Officer
Oncoinvent
TK
Tore Kvam
Chief Financial Officer
Oncoinvent
LP
Lars Prestegarden
Co-founder and Chief Executive Officer
Cytovation
FG
Federico Grego
Chief Operating Officer and Chief Financial Officer
Cytovation
DC
Diane Cowie
Head of CMC
Cytovation
DA
David A. Ricks
Chairman and Chief Executive Officer
Eli Lilly
AA
Anat Ashkenazi
Executive Vice President and Chief Financial Officer
Eli Lilly
DM
Daniel M. Skovronsky
Chief Scientific and Medical Officer, President of Lilly Research Laboratories
Eli Lilly
AE
Anne E. White
Executive Vice President and President of Lilly International
Eli Lilly
PJ
Patrik Jonsson
Executive Vice President, President of Lilly USA
Eli Lilly
IY
Ilya Yuffa
Executive Vice President and President of Lilly Manufacturing Operations
Eli Lilly
CS
Christi Shaw
Executive Vice President and President of Lilly Oncology
Eli Lilly
MM
Mike Mason
Executive Vice President and President of Lilly Diabetes
Eli Lilly
RG
Ruth Gimmi
Executive Vice President, Chief Information and Digital Officer
Eli Lilly
MB
Melissa Barnes
Executive Vice President, Global Quality
Eli Lilly